These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8011845)

  • 1. Pyrimethamine as primary prophylaxis of toxoplasmic encephalitis in patients infected with human immunodeficiency virus: open study.
    Bachmeyer C; Gorin I; Deleuze J; Morini JP; Escande JP
    Clin Infect Dis; 1994 Mar; 18(3):479-80. PubMed ID: 8011845
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
    Schürmann D; Bergmann F; Albrecht H; Padberg J; Wünsche T; Grünewald T; Schürmann M; Grobusch M; Vallée M; Ruf B; Suttorp N
    Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group.
    Leport C; Chêne G; Morlat P; Luft BJ; Rousseau F; Pueyo S; Hafner R; Miro J; Aubertin J; Salamon R; Vildé JL
    J Infect Dis; 1996 Jan; 173(1):91-7. PubMed ID: 8537688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An audit of the use of prophylaxis against toxoplasmic encephalitis in HIV disease.
    Fox E; Dean G; de Ruiter A
    Int J STD AIDS; 1998 Mar; 9(3):177-9. PubMed ID: 9530907
    [No Abstract]   [Full Text] [Related]  

  • 5. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
    Opravil M; Hirschel B; Lazzarin A; Heald A; Pechère M; Rüttimann S; Iten A; von Overbeck J; Oertle D; Praz G
    Clin Infect Dis; 1995 Mar; 20(3):531-41. PubMed ID: 7756472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials Group.
    Rousseau F; Pueyo S; Morlat P; Hafner R; Chène G; Leport C; Luft BJ; Miro J; Aubertin J; Salamon R; Vildé JL
    Clin Infect Dis; 1997 Mar; 24(3):396-402. PubMed ID: 9114191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS.
    Schürmann D; Bergmann F; Albrecht H; Padberg J; Grünewald T; Behnsch M; Grobusch M; Vallée M; Wünsche T; Ruf B; Suttorp N
    J Infect; 2001 Jan; 42(1):8-15. PubMed ID: 11243747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
    Girard PM; Landman R; Gaudebout C; Olivares R; Saimot AG; Jelazko P; Gaudebout C; Certain A; Boué F; Bouvet E
    N Engl J Med; 1993 May; 328(21):1514-20. PubMed ID: 8479488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group.
    Derouin F; Leport C; Pueyo S; Morlat P; Letrillart B; Chêne G; Ecobichon JL; Luft B; Aubertin J; Hafner R; Vildé JL; Salamon R
    AIDS; 1996 Nov; 10(13):1521-7. PubMed ID: 8931787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxoplasmosis in HIV-positive women: seroprevalence and the role of prophylaxis in preventing disease.
    Ruiz R; Cu-Uvin S; Fiore T; Flanigan TP
    AIDS; 1997 Jan; 11(1):119-20. PubMed ID: 9138460
    [No Abstract]   [Full Text] [Related]  

  • 11. Discontinuation of secondary prophylaxis for toxoplasmic encephalitis in human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy.
    Guex AC; Radziwill AJ; Bucher HC
    Clin Infect Dis; 2000 Mar; 30(3):602-3. PubMed ID: 10722454
    [No Abstract]   [Full Text] [Related]  

  • 12. Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus.
    Richards FO; Kovacs JA; Luft BJ
    Clin Infect Dis; 1995 Aug; 21 Suppl 1():S49-56. PubMed ID: 8547512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro synthesis of antibodies to Toxoplasma gondii by lymphocytes from HIV-1-infected patients.
    Vendrell JP; Reynes J; Huguet MF; Ngou J; Michard C; Atoui N; Pratlong F; Segondy M; Serre A
    Lancet; 1993 Jul; 342(8862):22-3. PubMed ID: 8100291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS.
    Jacobson MA; Besch CL; Child C; Hafner R; Matts JP; Muth K; Wentworth DN; Neaton JD; Abrams D; Rimland D
    J Infect Dis; 1994 Feb; 169(2):384-94. PubMed ID: 8106772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis.
    Connolly MP; Goodwin E; Schey C; Zummo J
    Pathog Glob Health; 2017 Feb; 111(1):31-44. PubMed ID: 28090819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing and management of Toxoplasma serology in HIV-seropositive patients.
    Aarons E; Hawkins D; Nelson M; Gazzard B
    AIDS; 1996 Apr; 10(4):443-4. PubMed ID: 8728051
    [No Abstract]   [Full Text] [Related]  

  • 17. [Primary prevention of toxoplasmosis in patients with HIV infection].
    Peńa JM; Vázquez JJ
    Med Clin (Barc); 1994 Apr; 102(16):621-3. PubMed ID: 8208039
    [No Abstract]   [Full Text] [Related]  

  • 18. Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group.
    Podzamczer D; Miró JM; Bolao F; Gatell JM; Cosín J; Sirera G; Domingo P; Laguna F; Santamaría J; Verdejo J
    Ann Intern Med; 1995 Aug; 123(3):175-80. PubMed ID: 7598298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The impact of the prevention of cerebral toxoplasmosis].
    Katlama C
    J Neuroradiol; 1995 Sep; 22(3):193-5. PubMed ID: 7472536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients.
    Ruf B; Schürmann D; Bergmann F; Schüler-Maué W; Grünewald T; Gottschalk HJ; Witt H; Pohle HD
    Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):325-9. PubMed ID: 8354297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.